The TGA has repeatedly warned that unapproved peptides pose safety risks because their quality and efficacy have not been assessed. It has taken robust enforcement action over the past decade, imposing or securing pecuniary penalties (ranging from a few thousand dollars up to $10 million) for advertising breaches: advertising unapproved and prescription medicines, referring to serious diseases or conditions in advertisements for peptides (so-called restricted or prohibited representations), and making misleading health claims.